Changes in alpha-fetoprotein and des-γ-carboxy-prothrombin after transarterial chemoembolization and their value in predicting treatment outcome

Yan LeLe; Ni CaiFang; Li Zhi; Hu Bo; Xu JiaChen

doi:10.3969/j.issn.1001-5256.2019.01.020

Volume 35 Issue 1

Jan. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(1): 109-113

PDF( 2094 KB)

Changes in alpha-fetoprotein and des-γ-carboxy-prothrombin after transarterial chemoembolization and their value in predicting treatment outcome

DOI: 10.3969/j.issn.1001-5256.2019.01.020

Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou， Jiangsu 215006, China

Research funding:

Published Date: 2019-01-20

Abstract

Abstract

Objective To investigate the value of alpha-fetoprotein (AFP) combined with des-γ-carboxy-prothrombin (DCP) in predicting the therapeutic effect of transarterial chemoembolization (TACE) .Methods A retrospective analysis was performed for the clinical data of 85 patients with hepatocellular carcinoma (HCC) who underwent TACE in The First Affiliated Hospital of Soochow University from October 2016 to March 2018.The serum levels of AFP and DCP were measured before TACE and after two consecutive sessions of TACE, and modified RECIST (mRECIST) was used to evaluate the therapeutic effect of TACE.The changes in AFP and DCP were compared with imaging findings based on mRECIST.The two-independent-samples t test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups.The chi-square test was used for comparison of categorical data between two groups, and the Mann-Whitney U test was used for comparison of ranked data between two groups.A Spearman correlation analysis was used to investigate the correlation of mRECIST category with AFP and DCP.The receiver operating characteristic (ROC) curve was used to investigate the value of each index in the diagnosis of remission.Results According to the mRECIST criteria, 38 patients achieved remission (remission group) and 31 did not achieve remission (non-remission group) .After treatment, the remission group had significantly lower AFP and DCP than the non-remission group (Z=-3.366 and-4.065, both P<0.05) .There were significant differences between the remission group and the non-remission group inΔAFP, ΔDCP, ΔAFP%, andΔDCP% (Z=-4.837, -5.597, -4.210, and-5.851, all P<0.001) .The mRECIST category was negatively correlated withΔAFP andΔDCP (rs=-0.552 and-0.593, both P<0.001) .In the diagnosis of remission, ΔAFP%had an area under the ROC curve (AUC) of 0.796, whileΔDCP%had an AUC of 0.912 andΔAFP%combined withΔDCP%had an AUC of0.921, suggesting thatΔAFP%combined withΔDCP%had the highest diagnostic value.Conclusion Changes in serum DCP and AFP after TACE can be used to evaluate the outcome of HCC after TACE.
- chemoembolization, therapeutic,
- carcinoma, hepatocellular,
- alpha-fetoproteins,
- des-gamma-carboxy-prothrombin,
- prognosis

FullText(HTML)

References(21)

References

[1]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.

[2]RAOUL JL, SANGRO B, FORNER A, et al.Evolving strategies for the management of intermediate-ate-stage hepatocellular carcinoma:Available evidence and expert opinion on the use of transarterial chemoembolization[J].Cancer Treat Rev, 2011, 37 (3) :212-220.

[3]LIANG YF, SHI L, SUN NN, et al.Analysis of the dynamic changes and clinic significance of serum CA724, CA242 and AFP levels before and after TACE treatment of primary hepatic carcinoma[J].Tianjin Med J, 2015, 43 (10) :1183-1186. (in Chinese) 梁育飞, 石亮, 孙宁宁, 等.CA724、CA242及AFP在肝癌TA-CE治疗前后的表达变化及临床意义[J].天津医药, 2015, 43 (10) :1183-1186.

[4]CUI HZ, WANG MC, XU AF, et al.Correlation analysis of alpha fetoprotein changes and therapeutic effect after transcatheter arterial chemoembolization[J].Chin J Health Lab Technol, 2018, 28 (10) :1220-1222. (in Chinese) 崔怀中, 王妙婵, 徐爱芳, 等.肝动脉栓塞化疗术后甲胎蛋白变化与疗效的相关性分析[J].中国卫生检验杂志, 2018, 28 (10) :1220-1222.

[5]LIN YY, CHEN Y, CHEN YS, et al.Clinical value of the abnormal prothrombin PVKIA-Ⅱin detection of hepatocellular carcinoma[J].Curr Immunol, 2015, 35 (4) :328-333. (in Chinese) 林莺莺, 陈燕, 陈岩松, 等.异常凝血酶原 (PIVKA-Ⅱ) 检测在肝细胞癌中的临床价值[J].现代免疫学, 2015, 35 (4) :328-333.

[6]National Health and Family Planning Commission of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) .中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[7] OKEN MM, CREECH RH, TORMEY DC, et al.Toxicity and response criteria of the eastern cooperative oncology group[J].Am J Clin Oncol, 1982, 5 (6) :649-655.

[8]LENCIONI R, LLOVET JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J].Semin Liver Dis, 2010, 30 (1) :52-60.

[9]SUN ZD, CHENG LM, PING P, et al.Analysis of the risk factors for prognosis of surgical treatment patients with primary liver cancer[J].J Clin Exp Med, 2017, 16 (12) :1204-1207. (in Chinese) 孙志德, 程利民, 平萍, 等.影响原发性肝癌患者手术治疗预后的危险因素分析[J].临床和实验医学杂志, 2017, 16 (12) :1204-1207.

[10]XIA DD, WANG EX, WANG WJ, et al.Early alpha-fetoprotein response can predict the prognosis of patients with intermediate-stage hepatocellular carcinoma trated with transarterial chemoembolization[J].J Clin Hepatol, 2017, 33 (6) :1120-1125. (in Chinese) 夏冬东, 王恩鑫, 王文军, 等.早期AFP应答对经肝动脉化疗栓塞术后中期肝细胞癌患者预后的预测价值[J].临床肝胆病杂志, 2017, 33 (6) :1120-1125.

[11]ZHENG HL, ZHAO R, LI DP, et al.Utility of DCP and AFP in diagnosis of primary liver cancer[J].Chin J Gen Prac, 2016, 14 (1) :29-31. (in Chinese) 郑海伦, 赵睿, 李大鹏, 等.肿瘤标志物DCP和AFP在原发性肝癌中的诊断价值[J].中华全科医学, 2016, 14 (1) :29-31.

[12]LIEBMAN HA, FURIE BC, TONG MJ, et al.Des-g-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma[J].N Engl J Med, 1984, 310 (22) :1427-1431.

[13]WANG QS.Application of serum abnormal prothrombin and alpha-fetoprotein in the diagnosis of primary hepatic carcinoma[J].J Shenyang Med Coll, 2017, 19 (4) :336-338. (in Chinese) 王全胜.血清异常凝血酶原和甲胎蛋白在原发性肝癌诊断中的应用[J].沈阳医学院学报, 2017, 19 (4) :336-338.

[14]ZHENG HL, ZHAO R, LI DP, et al.The significance of the level changes of serum DCP and AFP before and after the intervention treatment in patients with primary hepatic carcinoma[J].Acta Acad Med Bengbu, 2014, 39 (8) :1012-1014. (in Chinese) 郑海伦, 赵睿, 李大鹏, 等.原发性肝癌患者介入治疗前后血清异常凝血酶原和甲胎蛋白变化的意义[J].蚌埠医学院学报, 2014, 39 (8) :1012-1014.

[15]ZHANG QL, XING XZ, ZHANG LY, et al.Clinical value of combined detection of pokemon, AFP-L3, AFP and DCP after transarterial chemoembolization for hepatocellular carcinoma[J].Anhui Med Pharm J, 2017, 21 (3) :468-471. (in Chinese) 张全乐, 邢喜芝, 张立英, 等.肝癌介入治疗前后原癌基因Pokemon、甲胎蛋白异质体、甲胎蛋白、脱γ-羧基凝血酶原联合检测的临床价值[J].安徽医药, 2017, 21 (3) :468-471.

[16]ICHIKAWA T, MACHIDA N, SASAKI H, et al.Early prediction of the outcome using tumor markers and mRECIST in unresectable hepatocellular carcinoma patients who underwent transartery chemoembolization[J].Oncology, 2016, 91 (6) :317-330.

[17]ARAI T, KOBAYASHI A, OHYA A, et al.Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization[J].Int J Clin Oncol, 2014, 19 (5) :871-879.

[18]PARK WH, SHIM JH, HAN SB, et al.Clinical utility of des-γ-car-boxy prothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J].J Vasc Interv Radiol, 2012, 23 (7) :927-936.

[19]ZHAO CH, ZHOU WF, CHEN WH, et al.Clinical significance ofα-fetoprotein in initial diagnosis of primary hepatic cancer?[J].J Clin Hepatol, 2013, 29 (9) :698-701. (in Chinese) 赵春华, 周文峰, 陈维华, 等.甲胎蛋白在原发性肝癌首诊中的价值[J].临床肝胆病杂志, 2013, 29 (9) :698-701.

[20]HU B, TIAN X, SUN J.Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma:A meta-analysis[J].Int J Mol Sci, 2013, 14 (12) :23559-23580.

[21]WU B, ZHOU J, LING G, et al.Calli Spheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma:A short-term efficacy and safety study[J].World J Surg Oncol, 2018, 16 (1) :69.

Relative Articles

[1]	Zhi LIU, Xiaohong DU, Wengang CHAI. Efficacy of des-γ-carboxy-prothrombin in the diagnosis of hepatocellular carcinoma and its association with the clinical features of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(10): 2014-2018. doi: 10.12449/JCH241014
[2]	Jing LU, Yamin ZHANG, Hua LI, Yan MIAO. Value of a scoring system based on the serum levels of alpha-fetoprotein and alkaline phosphatase in predicting the prognosis of patients with resectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(3): 599-605. doi: 10.3969/j.issn.1001-5256.2023.03.017
[3]	Wang ZheXuan, Wang EnXin, Xia DongDong, Bai Wei, Wang QiuHe, Yuan Jie, Li XiaoMei, Niu Jing, Guo WenGang, Li Kai, Yin ZhanXin, Han GuoHong. Value of Child-Pugh score versus albumin-bilirubin grade in predicting the prognosis of unresectable hepatocellular carcinoma treated by transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2020, 36(1): 113-117. doi: 10.3969/j.issn.1001-5256.2020.01.025
[4]	Cha JunHao, Guo JinHe. Value of abnormal prothrombin in evaluating the short-term efficacy of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(9): 1990-1993. doi: 10.3969/j.issn.1001-5256.2020.09.016
[5]	Xi LiTing, Zhang HuiXian, Wu AiRong, Xu ChunFang, Zhu JinZhou. Value of combined measurement of serum alpha-fetoprotein, Dickkopf-1, and cytoskeleton-associated protein 4 in diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(6): 1276-1279. doi: 10.3969/j.issn.1001-5256.2019.06.019
[6]	Ye YingJian, Liu Bo, Chen Wei, Li QiongXia. Prognosis and staging system analysis of hepatocellular carcinoma patients with negative serum alpha-fetoprotein[J]. Journal of Clinical Hepatology, 2019, 35(3): 535-541. doi: 10.3969/j.issn.1001-5256.2019.03.017
[7]	Sun Yu, Zhang HongHai, Yuan ChunWang, Li Cong, Hu CaiXia, Cui ShiChang, Zhang YongHong, Zheng JiaSheng. Change in serum level of abnormal prothrombin after microwave ablation for hepatocellular carcinoma and its clinical significance[J]. Journal of Clinical Hepatology, 2019, 35(3): 542-546. doi: 10.3969/j.issn.1001-5256.2019.03.018
[8]	Deng WeiWei, Zhu WenMing, Yi Chao, Feng YangChun, Huang YanChun. Association of serum interleukin-17 level with early recurrence and prognosis after radical surgery in hepatocellular carcinoma patients with different levels of alpha-fetoprotein[J]. Journal of Clinical Hepatology, 2018, 34(2): 298-302. doi: 10.3969/j.issn.1001-5256.2018.02.016
[9]	Sun Yu, Zhang HongHai, Yuan ChunWang, Hu CaiXia, Liu BoJun, Cui ShiChang, Qian ZhiLing, Zhang YingHua, Zhang YongHong, Zheng JiaSheng. Value of serum des-γ-carboxy-prothrombin in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(10): 2148-2152. doi: 10.3969/j.issn.1001-5256.2018.10.017
[10]	Lu NingNing, Zhang YingHua, Wang HaiYan, Gao WenFeng, Zheng JiaSheng. Value of serum alpha-fetoprotein and protein induced by vitamin K absence or antagonist-Ⅱ in pathological diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(11): 2162-2165. doi: 10.3969/j.issn.1001-5256.2017.11.022
[11]	Lu FengMin. Serological diagnosis of hepatocellular carcinoma:challenges and opportunities[J]. Journal of Clinical Hepatology, 2017, 33(7): 1262-1265. doi: 10.3969/j.issn.1001-5256.2017.07.011
[12]	Xia DongDong, Wang EnXin, Wang WenJun, Bai Wei, Yuan Jie, Han GuoHong. Early alpha-fetoprotein response can predict the prognosis of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2017, 33(6): 1120-1125. doi: 10.3969/j.issn.1001-5256.2017.06.021
[13]	Wen Jun, Li Jia, Wang ChunYan, Ma Ying. Value of serum PIVKA-Ⅱ, alpha-fetoprotein, and ferritin in assisting the diagnosis of HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(9): 1729-1733. doi: 10.3969/j.issn.1001-5256.2017.09.020
[14]	Zhang Cheng, Qi XingShun, Bo Ming, Zhao Yan, Wang WeiJuan, Han GuoHong. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma complicated by portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2016, 32(1): 84-87. doi: 10.3969/j.issn.1001-5256.2016.01.014
[15]	Ma ShiJie, Zou ShaoJing, Luo XiaoLing, Li QianJun, Huang JiaSheng. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 80-83. doi: 10.3969/j.issn.1001-5256.2016.01.013
[16]	Bai LiQing, Qiao JiaNi. Expression and correlation analysis of γ-glutamyl transpeptidase and alpha-fetoprotein in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(9): 1452-1454. doi: 10.3969/j.issn.1001-5256.2015.09.021
[17]	Gao HaiFeng. Value of combined detection of serum AFP and GP73 in early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(7): 660-662. doi: 10.3969/j.issn.1001-5256.2014.07.022
[18]	Gao Chun, Fang Long, Yao ShuKun. Correlation of GGT with AFP and diagnostic value of GGT for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(9): 921-925. doi: 10.3969/j.issn.1001-5256.2014.09.021
[19]	Jia Jia, Qi XingShun, Han GuoHong. Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(8): 576-580. doi: 10.3969/j.issn.1001-5256.2013.08.006

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	莫鹏，郭杏春，梁秀娟，王耀明. 超声引导与CT引导射频消融治疗肝细胞癌患者疗效及预后比较. 中华消化病与影像杂志(电子版). 2024(02): 151-154 .
2.	章琦，张文峰，李雷，邓琼. 血必净注射液对中晚期肝癌化疗栓塞后综合征的临床疗效和相关机制研究. 药品评价. 2024(05): 582-584 .
3.	周西，刘启榆，王忠，范丹丹，温凌字，杨伟. 能谱CT联合血清AFP、VEGF在肝细胞癌患者TACE术后随访中的应用价值. 中西医结合肝病杂志. 2022(06): 548-552 .
4.	李莹莹，朱晓东，冯兴勇，余洁，邹佳华. 血浆组织因子微粒、脱-γ-羧基凝血酶原、神经元特异性烯醇化酶在胃癌患者血液高凝状态中的临床价值. 国际检验医学杂志. 2022(21): 2677-2679+2688 .
5.	余微微，李秋艳，罗云程，虞希祥. 异常凝血酶原在肝癌临床诊疗中的应用价值. 介入放射学杂志. 2021(11): 1193-1196 .
6.	郑柯. CT增强扫描与MRI在诊断原发性肝癌患者中临床价值. 临床研究. 2021(12): 126-128 .
7.	孙德生，徐宏伟，徐惠亮，陈建尧，杨月明，施涛，沈郁. 甲胎蛋白水平与中晚期原发性肝癌TACE术后疗效和预后的相关性分析. 中国现代医生. 2021(35): 1-4 .
8.	孙冬雪，杨柱，龙奉玺，魏显鳗，唐东昕. 康莱特注射液联合经肝动脉化疗栓塞术治疗中晚期肝癌效果的Meta分析. 临床肝胆病杂志. 2020(02): 363-368 . 本站查看

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1891) PDF downloads(334)

Changes in alpha-fetoprotein and des-γ-carboxy-prothrombin after transarterial chemoembolization and their value in predicting treatment outcome

DOI: 10.3969/j.issn.1001-5256.2019.01.020